Cochlear Limited
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more
Market Cap & Net Worth: Cochlear Limited (CHEOF)
Cochlear Limited (PINK:CHEOF) has a market capitalization of $10.37 Billion ($10.37 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #1646 globally and #1223 in its home market, demonstrating a -1.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cochlear Limited's stock price $158.55 by its total outstanding shares 65398548 (65.40 Million).
Cochlear Limited Market Cap History: 2015 to 2025
Cochlear Limited's market capitalization history from 2015 to 2025. Data shows growth from $3.73 Billion to $10.37 Billion (12.39% CAGR).
Cochlear Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cochlear Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.43x
Cochlear Limited's market cap is 4.43 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
26.66x
Cochlear Limited's market cap is 26.66 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.99 Billion | $1.13 Billion | $188.92 Million | 4.42x | 26.42x |
| 2017 | $7.75 Billion | $1.25 Billion | $223.62 Million | 6.18x | 34.64x |
| 2018 | $7.14 Billion | $1.36 Billion | $245.80 Million | 5.24x | 29.07x |
| 2019 | $8.39 Billion | $1.43 Billion | $276.70 Million | 5.88x | 30.32x |
| 2020 | $9.73 Billion | $1.32 Billion | -$238.30 Million | 7.37x | N/A |
| 2021 | $9.66 Billion | $1.50 Billion | $326.50 Million | 6.45x | 29.58x |
| 2022 | $8.47 Billion | $1.65 Billion | $289.10 Million | 5.14x | 29.30x |
| 2023 | $12.66 Billion | $1.94 Billion | $300.60 Million | 6.54x | 42.12x |
| 2024 | $12.32 Billion | $2.24 Billion | $356.80 Million | 5.51x | 34.52x |
| 2025 | $10.37 Billion | $2.34 Billion | $388.90 Million | 4.43x | 26.66x |
Competitor Companies of CHEOF by Market Capitalization
Companies near Cochlear Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Cochlear Limited by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Cochlear Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Cochlear Limited's market cap moved from $3.73 Billion to $ 10.37 Billion, with a yearly change of 12.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.37 Billion | -15.83% |
| 2024 | $12.32 Billion | -2.70% |
| 2023 | $12.66 Billion | +49.48% |
| 2022 | $8.47 Billion | -12.30% |
| 2021 | $9.66 Billion | -0.72% |
| 2020 | $9.73 Billion | +15.94% |
| 2019 | $8.39 Billion | +17.42% |
| 2018 | $7.14 Billion | -7.76% |
| 2017 | $7.75 Billion | +55.17% |
| 2016 | $4.99 Billion | +33.92% |
| 2015 | $3.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cochlear Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.37 Billion USD |
| MoneyControl | $10.37 Billion USD |
| MarketWatch | $10.37 Billion USD |
| marketcap.company | $10.37 Billion USD |
| Reuters | $10.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.